Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Orion, Webcast, Q1'26

By Inderes4/23/2026, 11:00 AM
Orion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Tuukka Hirvonen
00:00 - 01:09

Good afternoon and welcome to Orion's Q1 2026 results webcast and conference call. My name is Tuukka Hirvonen and I am the head of IR here at Orion. In a few moments, we will kick off with the presentation by our CEO, Lisa Herman, after which you will have the possibility to ask questions either from Lisa or from our CFO, Rene Lindell. We will be first taking the questions through the conference call lines, and after that we will turn on to the webcast chat function. So you may also type in your questions using the chat function of this webcast. And to our Finnish speaking viewers. This event is held in English, but afterwards, later this afternoon, you will find a Finnish interview of Orion CEO Lisa Herman on Orion's website. And before letting Lisa step in, just a reminder about this disclaimer regarding forward-looking statements. With these words, I'd like to hand over to Lisa.

Lisa Herman
01:10 - 15:35

Thank you and good afternoon on my behalf as well. And welcome to listen to Orion. Q1 2026 results. Some highlights from this Q1: all our businesses performed solidly and very well, I would say so. And we also have good news regarding our clinical pipeline. We have been granted orphan drug designation for ODM 212 in mesothelioma by FDA in April. And we also started a new Phase 1b/2 study called TEADCO, which is a basket trial evaluating ODM-212 in combination with standard of care treatments in patients with selected advanced solid tumors. And I will talk more about that later on. Also, we have strengthened our executive team by appointing Mr. Berkeley Vincent has been appointed as an Executive Vice President to lead Innovative Medicines Division and as a member of my executive team. As of April 8th. So let's look at the financials. Net sales saw a healthy growth of almost 18% compared to the previous year's Q1. Also, operating profit grew by 47%, which brought us to an operating profit margin of 27.5%, and earnings per share increased by 7%. Looking at net sales in more detail. Innovative Medicines drove the net sales growth with royalties and tablet sales. But as mentioned. As I already mentioned, all the divisions are performing well. Of course, in relation to the size of the division. So, Branded Products growth was 5.2 million, Generics 1.9 million, and Animal Health 1.1 million. And even Fermion external sales grew 1.8 million, totaling €480 million of net sales during Q1. And the operating profit consists, of course, of the royalties here in column three, close to €41 million, and a change in sales volume of €21 million. We of course, see some effect on decreasing prices as we usually see, the biggest products suffering from this are, of course, Simdax and Dexdomitor, but there are other generics as well. This comprises €9.3 million. That also includes effects and changes in cost of goods. No major milestones received in Q1. And then we also see an increase in our fixed costs. And thus our operating profit was close to €150 million during Q1. Now to Innovative Medicines, the division growth was close to 54%. And here we can see the Nubeqa royalties and tablet sales. The total is 145. Close to €145 million. Some other business of €5.4 million, which is usually sales of services to our partners. Sales of services to our partners, resulting in €150 million of net sales. And as we remember from the previous years, we start with the lower royalty rate from Bayer in the beginning of the year. So the royalties are tiered during the financial year. And we see in Q1 clearly a lower Nubeqa income compared to the last quarter of the previous year, but clearly a higher Nubeqa revenue compared to the prior year's Q1, with royalties at €95 million and tablet sales to Bayer at €50 million. Branded Products saw close to 7% growth compared to the previous year, with €82.2 million. Easyhaler continues to drive growth in this division, especially budesonide Formoterol, as the recent changes in treatment guidelines from last year favor the use of combination products over the mono products, and we've been able to really increase our sales according to this new guideline. And the good growth momentum in women's health therapy area continues with the HRT products. Generics and Consumer Health 1.4% growth. It's according to market growth, maybe slightly below that. But this is only one quarter. And we all know that this is really a very wide portfolio in many different geographies. So this is a very good achievement for the first quarter, and Animal Health 3.3% growth. Of course, again, a very wide portfolio both for companion animals and livestock and a global portfolio. And the growth comes from all of the different geographies and both segments or both units. When we look at the top ten products, of course, we see the Nubeqa as we discussed driving the growth. Easyhaler 7% growth. Entacapone was slightly down compared to the previous year's first quarter. But this is mainly again, a timing issue of deliveries to different regions and different partners. Same goes with the Dexdomitor and the Animal Health DDA portfolio number four here, which grows almost 11%. And that is again a result of delayed deliveries leaving during Q1. And as I mentioned, women's health continues good growth trajectory with almost 15% growth and Burana slightly decreasing almost 6%. That's also more of a timing issue and depends on the season. But then we see three of our generics, Trexan, Quetiapine and Fareston, which have a very, very healthy growth. This is partly due to the previously mentioned timing of deliveries to our partners, but also showing that, for example, Trexan is a gold standard treatment globally, used both in cancer and autoimmune diseases, and also has a solid position in our top ten products. As I already mentioned, Simdax is facing heavy generic competition in Europe. Now, Innovative Medicines during Q1 comprised 36% of our net sales, Generics 32%, and Branded Products 20%. Animal Health and Fermion together were 11% to 12% of our net sales. Our clinical development pipeline has now expanded. The list is now a bit longer with the new combination study for ODM 212, but I'll go through the list to remind us what we have now going on. So the two first ones are studies on Nubeqa, the DASL-HiCaP for the neoadjuvant use of darolutamide in prostate cancer. ARASTEP for the biochemically recurring prostate cancer. Omaha three and four are studies for metastatic castration-resistant prostate cancer with opevesostat, a molecule that Orion has developed and then outlicensed to MSD. Then, a somewhat odd product on this list, which otherwise features oncology products or molecules, is levosimendan. It's an old classic from Orion's portfolio, the same molecule as we have in Simdax. And that's developed for pulmonary hypertension. And there are two Phase 3 studies ongoing with that by our partner Tenox. Then there are phase two studies again with Opevesostat for women's cancers like breast, endometrial, and ovarian cancer. These are by MSD. And this is, of course, to test whether this mechanism of action would also work for hormonal cancers in women. CYPIDES is still ongoing. That was the phase two study that was used when the phase three studies with Opevesostat started. So the results of that study were used for planning of those phase three studies. Those phase three TEADES is a monotherapy study, a phase two study for ODM 212 for malignant pleural mesothelioma and also for epithelioid hemangioma. Endothelioma. These are two very rare cancers, solid tumours, and we think that this molecule, based on its mechanism of action, should have a direct anti-tumor activity to these cancer types. And the newest addition, TEADCO, refers to combinations. The indications here the cancers are mesothelioma, non-small cell lung cancer, and pancreatic cancer. Here we are combining ODM 212 with some known drugs that are used for these specific cancers. And we use another mechanism of inhibition to combat or prevent the drug resistance that patients usually show to these currently used treatments. Here are some key figures from Orion's sustainability programs. Some key figures of Orion sustainability programs. We've been able to decrease our greenhouse gas emissions by 13%. And this is scope one and two. So it doesn't include Scope 3. Our injury rate is 4.9. And there is clearly room for improvement this year. We have very ambitious targets for LTIF. And then two things regarding the Code of Conduct, or how we operate within our own company and with our suppliers. This has to do with the Code of Conduct in Orion. 98% of our employees have completed the training for our Code of Conduct. Also, we conduct this Code of Conduct training and agreement with our suppliers, and 96% of our suppliers also adhere to it. Code of conduct. Our third-party Code of Conduct practices. We have specified our outlook for this year. We gave our outlook in January, and now after Q1, when a fourth of the year has already passed, we are a bit wiser and are able to increase the lower limit of our range by 50 million, both on net sales and operating profit. So, the net sales range was 1.9 billion to €2.1 billion. In the original outlook, and now it's from €1.95 billion to €2.1 billion. And same with the operating profit, which was previously 550 million to 750 million. And now it's from €600 million to €750 million. And here are some upcoming events for this year. And I think at this point, I thank you for your attention and I think it's time for questions.

Tuukka Hirvonen
15:37 - 15:51

Yes, thank you, Lisa, for the presentation and setup for today. And now let's turn to the questions. We will first take questions on the conference call line. So at this point, I would like to hand over to the operator.

Operator
15:53 - 16:11

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Alex Moore from Bank of America. Please go ahead.

Alex Moore
16:13 - 17:02

Hi there. Thanks for taking my questions. Two from me, both on Nubeqa. So you've previously mentioned that quarterly royalty reporting can be impacted by last month estimates and some reconciliation effects. I was just wondering for Q1, was there any particular conservatism or phasing assumptions baked into your sales estimate for March? And then separately, can you give any high level color on whether the reconciliation sales in December was meaningfully positive or negative? In terms of your reported royalty for the quarter? And then secondly, based on your current assumptions for full year sales run rate and tiered royalty rate, do you see consensus expectations of around 50% growth for Nubeqa sales this year as achievable? Thank you.

Rene Lindell
17:04 - 18:16

Maybe we can take that one. So I'll start first with December numbers. So we always try if possible to close the year with the actual reports and that we managed to do last year. So there was no reconciliation or carryover from 2025 to 2026. Naturally, as we said, the last month of the quarters within the year are based on estimates that we then have and the latest data. And then we'll be updating in the second quarter, and then we will discuss that, of course, in Q2. But we are not giving details between the months of how the Nubeqa accruals and actuals go, and we are very happy, of course, that Bayer is also optimistic on the full-year outlook for Nubeqa. And so are we. And of course, we do our own scenarios and try to make a balanced outlook for the year. That includes various scenarios. But other than that, not commenting on Bayer's estimates.

Operator
18:40 - 18:44

The next question comes from Sami Sarkamies from Danske Bank Markets. Please go ahead.

Andy Rossi
18:48 - 19:08

Hi. I have two questions starting from the guidance Upgrade. I think you mentioned that you were just wiser after Q1. Can you specify whether the upgrade was just based on Q1 performance, or have you also upgraded assumptions related to the rest of the year?

Rene Lindell
19:10 - 20:27

Yes, maybe I can comment on that. So as Lisa said, of course, we have one quarter behind us and that was solid across the businesses. And also, I think Nubeqa performing very nicely in the numbers and in the market. So I think it's a general point. I think if we look at the lower boundary, we also see that the probability for the lower limit of that old outlook starts to be quite low, and it made sense to raise that lower limit a bit higher. And when it comes to other aspects, some also result from the fact that we have a little bit more information. The USA tariffs for Pharma for this year, with the impact earliest for the October quarter, and as that information came through, that also reduces a little bit of the downside risk. That being said, it is still uncertain as it is still not in place and will be tested at the end of the year, what the impact will be, if any, at that point of time.

Andy Rossi
20:31 - 21:05

Okay. And then my second question would be related to Nubeqa product deliveries. These grew only 30% in Q1. I think they were also a bit small in Q4. So, should we just assume that inventories at Bayer have become lower in the last couple of quarters? And these product deliveries will pick up at some point in time during the rest of the year.

Lisa Herman
21:07 - 22:10

Well, I think the tablet deliveries from Orion to Bayer are not a very good—I would say not a very good—lead indicator for how Nubeqa sales would develop or how the inventories are, as the supply chain is really, really long. If you think the global supply chain. So, I would advise not to look at that tablet number or tablet sales; we ship according to Bayer's forecasts, and for the shipments, there is the same factor as for any other shipments, which is that sometimes they leave on a certain last day of a certain month or then the first day of the next month. So there might also be big changes, or big differences depending on when the shipments leave Orion. So that's not a very good and reliable indicator for forecasting inventories or future sales.

Rene Lindell
22:11 - 22:24

Perhaps I can continue here a little bit by adding that we do expect for the full year that we will have higher tablet deliveries than what we had in Q1. So it wasn't yet, I think, representative of the average level.

Lisa Herman
22:24 - 22:27

No, no. This is exactly what I mean. And yeah.

Andy Rossi
22:30 - 22:59

Okay. And then, I have one more question regarding the new combination study for ODM 212. Can you tell a bit more about the study? How many patients will be recruited? When are you expecting readouts? And then it would be interesting to hear what is currently the market for the drugs that you will be combining ODM-212 with.

Lisa Herman
23:01 - 23:50

I think I'll start with the studies. These are not huge studies. I don't have the exact number of patients unless my colleagues here have that. But let's remember that both of these indications, even though they are big ones. So we are now carrying out Phase 1b/2. So we are first trying different dosing with some of the combined drugs. For the results and readouts, I would be on the safe side to say that we can expect those during 2028 and the markets for the drugs that we are combining. I'm not going to share here the market details of those drugs, but those are listed. The ones that we combine with are listed in the press release currently.

Tuukka Hirvonen
23:56 - 23:58

Okay. Indications.

Andy Rossi
24:03 - 24:03

Yeah.

Tuukka Hirvonen
24:03 - 24:03

Yeah.

Andy Rossi
24:08 - 24:16

Okay. So assuming a sort of positive readout in 28, you probably still need to do additional studies for these patients.

Lisa Herman
24:17 - 24:17

Yes.

Andy Rossi
24:22 - 24:33

Yeah. And maybe on the market potential, think about the drugs that you are combining with. I mean, are these blockbuster products.

Lisa Herman
24:35 - 24:39

Oh yes. Indeed. Some of them are.

Tuukka Hirvonen
24:40 - 25:05

They are. But then again, one needs to remember that their indication may be wider than the one we are targeting with this combination. So we have listed the active ingredients in the press release we announced earlier this morning. So with that, you can definitely find out the brand names for these products. But again, please bear in mind that their indication may be wider than the one we are targeting with these trials.

Andy Rossi
25:09 - 25:12

Okay. Thank you. I don't have any further questions.

Operator
25:17 - 25:21

The next question comes from Mahdi Khairallah from OP Corporate Bank. Please go ahead.

Mahdi Khairallah
25:24 - 25:43

Hi. Thank you for getting my question. First thing, the royalty rate. So, what should we think about during this Q1? Is it comparable to what we saw last year, first quarter, or is it higher now? The sales have of course grown from Q1 last year.

Tuukka Hirvonen
25:45 - 25:50

The line was a bit bad. Right now there's somewhat of an echo. Could you please repeat your question?

Mahdi Khairallah
25:53 - 26:11

All right. Hopefully it's better now. Yeah, I was asking about the royalty rate during the Q1. So is it at the same level as last year or is it higher now as the Nubeqa sales grew from last year.

Rene Lindell
26:13 - 26:26

I don't think we comment on the royalty rates in that perspective as to where the tier breakpoints are. So you'll have to probably wait for that calculation to be done a bit later during the year.

Tuukka Hirvonen
26:27 - 26:42

But as a base assumption, each and every year when we are growing faster compared to previous year, we will be reaching the higher tiers earlier than last year. So in that sense, in Q1 also, probably the average is somewhat higher than last year.

Mahdi Khairallah
26:45 - 27:02

All right. Maybe then another question regarding the sales and marketing costs as they've been increasing. So could you roughly say how much of these are actual costs and how much are royalties? These are causing the cost growth.

Rene Lindell
27:06 - 27:29

Of course. And the royalties are playing a role in that. But we have also added a sales force to support, especially Branded Products in some European countries. So you will see both effects there visible. And of course, with Nubeqa growing quite a lot from last year's Q1. Then of course, those will be also visible in the sales and marketing.

Mahdi Khairallah
27:32 - 28:03

Then one more question regarding the R&D pipeline. So, as you said, there is this one unique study which is not covering oncology. So, I think it was last year exactly when you were putting this study into your pipeline. And could you remind us what was the reason to add that study back then to your pipeline? Why it was not there prior to your Phase 1 result?

Lisa Herman
28:03 - 28:38

Yes, that's a very good question. And thank you for asking so that we can remind. I think that was the time when Tenax started the Phase 3 program for pulmonary hypertension. They had been working with Levosimendan for a while, doing some confirmatory studies, but that was exactly the time when, when they were able to start the first study. And then eventually last year, they started the second study for pulmonary hypertension. So there is no other reason for that.

Mahdi Khairallah
28:41 - 28:43

Okay. No further questions.

Operator
28:48 - 28:59

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Andy Rossi from Seb. Please go ahead.

Andy Rossi
29:02 - 29:29

Hi all. Yes, it's Andy Rossi from Seb. One question from me regarding Nubeqa. So when we think about this early stage indication for Nubeqa, what would be a reasonable timeline to expect that you would jump in, which would of course trigger this expense for you? Because I have understood that Bayer is solely responsible for the development for now.

Lisa Herman
29:31 - 29:41

Indeed, this relates to the DASL-HiCaP study and the readout for this study, if I remember correctly, is 2028.

Tuukka Hirvonen
29:41 - 29:43

Estimated in 2028.

Lisa Herman
29:43 - 29:53

Estimated in 28. And I think that the latest point for us to jump in and exercise our option would be when we see the results of the study.

Andy Rossi
29:56 - 29:59

Okay. That's clear. Thank you. Nothing else from me.

Operator
30:03 - 30:08

The next question comes from Iris Titman from NB Carnegie. Please go ahead.

Iris Titman
30:10 - 30:20

Hi. I have just one question. So, what pipeline updates do you expect in the next 12 to 18 months? Thanks.

Lisa Herman
30:23 - 31:03

I'll start with our ambition to initiate at least one Phase 1 study with our biologics by the end of 2026. And then if you ask for the next 12 months, of course, then we move to 27. And there I hope to see another biologic entering clinical stage. So I think those are the major initiations of new projects. And then regarding the results, no major results that we would be expecting this year.

Tuukka Hirvonen
31:03 - 31:10

With the exception of the Levosimendan trial. Phase three trial by Tenax in Q3 this year.

Unknown 1
31:10 - 31:10

This year.

Lisa Herman
31:11 - 31:26

Thank you. But then in 27, the ARASTEP will be there will be a readout for ARASTEP in 27. Then again, what else did we have in 27?

Tuukka Hirvonen
31:26 - 31:51

The current estimate for the women's trials with Opevesostat is the end of 2027. We'll see how that pans out. And also for our first ODM-212 Phase-2. So with the monotherapy trial, current estimate is also in the end of 27. But it may move either direction depending on recruitment rates and so forth.

Iris Titman
31:56 - 32:03

Okay. And anything about Opevesostat ODM-212 for prostate cancer.

Lisa Herman
32:03 - 32:06

The readout for both of the studies is 28.

Tuukka Hirvonen
32:06 - 32:12

Yeah. The estimated final readout is in summer 28 for both of these trials.

Iris Titman
32:15 - 32:15

Okay. Thank you.

Operator
32:20 - 32:26

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Tuukka Hirvonen
32:27 - 32:55

Thank you. Operator. Then we'll turn to the webcast questions. So again, you still have the opportunity to type in your questions by using the webcast chat if you wish. We have one question here. One question coming from Sean Hammer from Jefferies. So Sean is interested to hear this. Could we please provide an update on Opevesostat timing and if we could still see interim data this year following Merck's comments in ASCO 2025. So last year.

Lisa Herman
32:56 - 33:16

I think I can only repeat what we said a minute ago that the readouts for both studies are estimated to happen in 2028. And regarding any interim results or interim analysis, I don't have information on that. So that should be asked from MSD.

Tuukka Hirvonen
33:18 - 33:33

Exactly. Thank you Lisa. We have no further questions either from the webcast. And I think that we also don't have any follow-ups on the conference call line. I think it's time to wrap up with some closing words. Lisa.

Lisa Herman
33:33 - 33:47

Yes, I thank you for your attention and very good questions. And of course, I hope that you will be attending our upcoming events this year and have a nice rest of the day. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…